April 28, 2020 / 11:54 AM / a month ago

BRIEF-Spectrum Pharmaceuticals Provides Strategy Update For Poziotinib Development Program

April 28 (Reuters) - Spectrum Pharmaceuticals Inc:

* SPECTRUM PHARMACEUTICALS PROVIDES STRATEGY UPDATE FOR POZIOTINIB DEVELOPMENT PROGRAM

* SPECTRUM PHARMACEUTICALS INC - ZENITH20 PHASE 2 CLINICAL TRIAL AMENDED TO INCLUDE NEW DOSING REGIMENS AIMED AT IMPROVING THERAPEUTIC INDEX Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below